Eiger BioPharmaceuticals Analyst Ratings
Eiger BioPharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/29/2023 | 248.88% | Citigroup | $4 → $3 | Maintains | Buy |
| 06/30/2023 | 481.46% | Baird | $3 → $5 | Maintains | Outperform |
| 09/07/2022 | 5482.04% | BTIG | $57 → $48 | Maintains | Buy |
| 08/09/2021 | 3039.9% | Citigroup | $26 → $27 | Maintains | Buy |
| 04/03/2020 | 3737.66% | Wedbush | $35 → $33 | Maintains | Outperform |
| 01/22/2020 | 3505.07% | Ladenburg Thalmann | $28 → $31 | Maintains | Buy |
| 06/26/2019 | 2458.44% | Citigroup | → $22 | Initiates Coverage On | → Buy |
| 01/29/2019 | 5365.75% | Baird | → $47 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月29日 | 248.88% | 花旗集團 | $4→$3 | 維護 | 買 |
| 2023/06/30 | 481.46% | 貝爾德 | $3→$5 | 維護 | 跑贏大盤 |
| 09/07/2022 | 5482.04% | BTIG | $57→$48 | 維護 | 買 |
| 08/09/2021 | 3039.9% | 花旗集團 | $26→$27 | 維護 | 買 |
| 04/03/2020 | 3737.66% | 韋德布什 | $35→$33 | 維護 | 跑贏大盤 |
| 2020/01/22 | 3505.07% | 拉登堡·塔爾曼 | $28→$31 | 維護 | 買 |
| 2019年06月26日 | 2458.44% | 花旗集團 | →$22 | 開始承保 | →購買 |
| 2019年01月29日 | 5365.75% | 貝爾德 | →$47 | 開始承保 | →跑贏大盤 |
What is the target price for Eiger BioPharmaceuticals (EIGR)?
艾格生物製藥(EIGR)的目標價是多少？
The latest price target for Eiger BioPharmaceuticals (NASDAQ: EIGR) was reported by Citigroup on August 29, 2023. The analyst firm set a price target for $3.00 expecting EIGR to rise to within 12 months (a possible 248.88% upside). 3 analyst firms have reported ratings in the last year.
花旗集團於2023年8月29日報道了艾格生物製藥(納斯達克：EIGR)的最新目標價。這家分析公司將目標價定為3美元，預計Eigr將在12個月內升至(可能上漲248.88)。3家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Eiger BioPharmaceuticals (EIGR)?
艾格生物製藥(EIGR)的最新分析師評級是多少？
The latest analyst rating for Eiger BioPharmaceuticals (NASDAQ: EIGR) was provided by Citigroup, and Eiger BioPharmaceuticals maintained their buy rating.
分析師對艾格生物製藥(納斯達克代碼：EIGR)的最新評級由花旗集團提供，艾格生物製藥維持買入評級。
When is the next analyst rating going to be posted or updated for Eiger BioPharmaceuticals (EIGR)?
艾格生物製藥(EIGR)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eiger BioPharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eiger BioPharmaceuticals was filed on August 29, 2023 so you should expect the next rating to be made available sometime around August 29, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公開財務報表，與艾格生物製藥的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。艾格生物製藥的上一次評級是在2023年8月29日提交的，所以你應該預計下一次評級將在2024年8月29日左右的某個時候公佈。
Is the Analyst Rating Eiger BioPharmaceuticals (EIGR) correct?
分析師對艾格生物製藥(EIGR)的評級正確嗎？
While ratings are subjective and will change, the latest Eiger BioPharmaceuticals (EIGR) rating was a maintained with a price target of $4.00 to $3.00. The current price Eiger BioPharmaceuticals (EIGR) is trading at is $0.86, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的艾格生物製藥(EIGR)評級維持不變，目標價在4.00美元至3.00美元之間。艾格生物製藥(Eigr)目前的交易價格為0.86美元，超出了分析師的預測區間。